Frazier Management News Today

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $8.46 and traded as high as $8.94. Alpine Immune Sciences shares last traded at $8.80, with a volume of 60,111 shares changing hands. Analyst Upgrades and […]

Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Rating) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 802,000 shares, an increase of 38.6% from the May 15th total of 578,600 shares. Approximately 1.4% of the company’s shares are sold short. Based on an average […]

Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) CEO Eric Dobmeier purchased 5,000 shares of the stock in a transaction on Wednesday, May 25th. The shares were purchased at an average cost of $13.03 per share, for a total transaction of $65,150.00. Following the acquisition, the chief executive officer now directly owns 205,880 shares of the […]

Equities research analysts forecast that Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) will announce earnings of ($0.95) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.88) and the lowest estimate coming in at ($1.02). Sierra […]

Analysts forecast that ESSA Pharma Inc. (NASDAQ:EPIX – Get Rating) (TSE:EPI) will post earnings of ($0.27) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for ESSA Pharma’s earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.29). ESSA Pharma posted […]

Autolus Therapeutics (NASDAQ:AUTL – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday, Zacks.com reports. The firm currently has a $3.00 target price on the stock. Zacks Investment Research‘s target price indicates a potential upside of 7.14% from the company’s current price. […]

Sierra Oncology (NASDAQ:SRRA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage currently has a $61.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside […]

Wall Street analysts predict that Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) will post earnings per share of ($0.25) for the current quarter, Zacks reports. Zero analysts have made estimates for Pardes Biosciences’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.27). The company is expected to issue its next earnings report […]

KalVista Pharmaceuticals (NASDAQ:KALV – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors […]

Equities research analysts forecast that Silence Therapeutics plc (NASDAQ:SLN – Get Rating) will report ($0.62) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Silence Therapeutics’ earnings. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st. On average, analysts expect that Silence […]